Jeffrey Sevigny's most recent trade in Rapport Therapeutics Inc. was a trade of 300,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc. | Jeffrey Sevigny | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Acumen Pharmaceuticals Inc | Jeffrey Sevigny | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Acumen Pharmaceuticals Inc | Jeffrey Sevigny | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) |